Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 18, Issue 5, Pages 683-695Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138161212799315975
Keywords
Inhaled antibiotics; Pseudomonas aeruginosa; cystic fibrosis; aerosol; lung delivery
Categories
Ask authors/readers for more resources
The field of inhaled antibiotics that target Pseudomonas aeruginosa infections has made substantial contributions to the health, disease management, and life expectancies of individuals with cystic fibrosis (CF) over the last three decades [1-3]. This paper reviews some of the recent clinical developments in the field of inhaled antibiotics for CF and briefly describes formulations and ongoing developments for US and/or European regulatory approvals. Lung delivery technologies, in regards to inhaled antibiotics for CF, are also reviewed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available